Movement Alert｜Innovent Biologics Rises 3.22% in Regular Trading, Technical Rebound After Multi-Day Decline as Biotech Sector Recovers

Market Focus06-12

On June 12, Innovent Biologics rose 3.22% in regular trading, trading at HK$74.45/share, with turnover of HK$228 million. The stock is rebounding after consecutive trading sessions of decline driven by regulatory uncertainty surrounding its US$10.5 billion strategic collaboration with Pfizer, which had sent shares from approximately HK$79.5 down to HK$72.1 over the prior week.

The broader biotech sector is showing signs of stabilization today, with Akeso up 1.71%, BeiGene up 0.64%, Remegen up 1.0%, and SKB Bio up 3.8%, providing supportive sentiment after days of systematic selling pressure. Additionally, Innovent recently secured priority review acceptance from China's NMPA for its CLDN18.2 ADC drug IBI343 in advanced gastric cancer, becoming the first globally to enter regulatory review in this target class, and presented multiple clinical results at the ADA annual meeting for its obesity and metabolic disease pipeline.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1186735727?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-12 10:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186735727","market":"us","top_or_hot":-1,"title":"Movement Alert｜Innovent Biologics Rises 3.22% in Regular Trading, Technical Rebound After Multi-Day Decline as Biotech Sector Recovers","media":"Market Focus","content":"<p><p>On June 12, Innovent Biologics rose 3.22% in regular trading, trading at HK$74.45/share, with turnover of HK$228 million. The stock is rebounding after consecutive trading sessions of decline driven by regulatory uncertainty surrounding its US$10.5 billion strategic collaboration with Pfizer, which had sent shares from approximately HK$79.5 down to HK$72.1 over the prior week.</p><p>The broader biotech sector is showing signs of stabilization today, with Akeso up 1.71%, BeiGene up 0.64%, Remegen up 1.0%, and SKB Bio up 3.8%, providing supportive sentiment after days of systematic selling pressure. Additionally, Innovent recently secured priority review acceptance from China's NMPA for its CLDN18.2 ADC drug IBI343 in advanced gastric cancer, becoming the first globally to enter regulatory review in this target class, and presented multiple clinical results at the ADA annual meeting for its obesity and metabolic disease pipeline.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Innovent Biologics Rises 3.22% in Regular Trading, Technical Rebound After Multi-Day Decline as Biotech Sector Recovers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Innovent Biologics Rises 3.22% in Regular Trading, Technical Rebound After Multi-Day Decline as Biotech Sector Recovers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-12 10:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 12, Innovent Biologics rose 3.22% in regular trading, trading at HK$74.45/share, with turnover of HK$228 million. The stock is rebounding after consecutive trading sessions of decline driven by regulatory uncertainty surrounding its US$10.5 billion strategic collaboration with Pfizer, which had sent shares from approximately HK$79.5 down to HK$72.1 over the prior week.</p><p>The broader biotech sector is showing signs of stabilization today, with Akeso up 1.71%, BeiGene up 0.64%, Remegen up 1.0%, and SKB Bio up 3.8%, providing supportive sentiment after days of systematic selling pressure. Additionally, Innovent recently secured priority review acceptance from China's NMPA for its CLDN18.2 ADC drug IBI343 in advanced gastric cancer, becoming the first globally to enter regulatory review in this target class, and presented multiple clinical results at the ADA annual meeting for its obesity and metabolic disease pipeline.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1186735727","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186735727","pubTimestamp":1781230227,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 12, Innovent Biologics rose 3.22% in regular trading, trading at HK$74.45/share, with turnover of HK$228 million. The stock is rebounding after consecutive trading sessions of decline driven...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"动静快讯|信达生物常规交易涨3.22%生物科技板块复苏连日下跌后技术性反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"On June 12, Innovent Biologics rose 3.22% in regular trading, trading at HK$74.45/share, with turnover of HK$228 million. The stock is rebounding after consecutive trading sessions of decline driven by regulatory uncertainty surrounding its US$10.5 billion strategic collaboration with Pfizer, which had sent shares from approximately HK$79.5 down to HK$72.1 over the prior week.The broader biotech sector is showing signs of stabilization today, with Akeso up 1.71%, BeiGene up 0.64%, Remegen up 1.0%, and SKB Bio up 3.8%, providing supportive sentiment after days of systematic selling pressure. Additionally, Innovent recently secured priority review acceptance from China's NMPA for its CLDN18.2 ADC drug IBI343 in advanced gastric cancer, becoming the first globally to enter regulatory review in this target class, and presented multiple clinical results at the ADA annual meeting for its obesity and metabolic disease pipeline.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1186735727","isCrawlerRequest":true}